| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Domperidone | Domperidone EP Impurity A | VL700001 | View CAS 53786-28-0 |
| Domperidone | Domperidone EP Impurity B | VL700002 | View CAS 1346598-11-5 |
| Domperidone | Domperidone EP Impurity C | VL700003 | View CAS 118435-03-3 |
| Domperidone | Domperidone EP Impurity D | VL700005 | View CAS 1614255-34-3 |
| Domperidone | Domperidone EP Impurity E | VL700006 | View CAS 1346602-50-3 |
| Domperidone | Domperidone EP Impurity F | VL700004 | View CAS 1391053-55-6 |
| Catalogue No. | VL700003 |
| CAS No. | 118435-03-3 |
| Molecular Formula | C₂₂H₂₄ClN₅O₃ |
| Molecular Weight | 441.91 |
| Parent drug | Domperidone |
| IUPAC Name | 5-Chloro-1-[1-[3-(2, 3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-1-oxido-4-piperidinyl]-1, 3-dihydro-2H-benzimidazol-2-one |
| Synonyms | Domperidone N-Oxide |
| References | Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache By Nathaniel M. Robbins, Hiroyuki Ito, Melvin M. Scheinman, Peter J. Goadsby Container: Neurology Year: 2016 Volume: 87 Issue: 24 DOI: 10.1212/wnl.0000000000003429 URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5206996/ |
| Status | In-stock |
| ListName | Domperidone EP Impurity C |
| Exclusively Supplied by Veeprho | Exclusively Supplied by Veeprho |
"*" indicates required fields
